Home > Insider Trading > Filing (0000914475-24-000096)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1643653	Eric Benevich	12780 El Camino Real San Diego CA 92130	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-14	5,479	$79.02	46,257	No	4	M	Direct
Common Stock	Disposition	2024-03-14	5,479	$139.38	40,778	No	4	S	Direct
Common Stock	Acquisiton	2024-03-14	69,521	$81.05	110,299	No	4	M	Direct
Common Stock	Disposition	2024-03-14	69,521	$139.38	40,778	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option	Disposition	2024-03-14	5,479	$79.02	5,479	$79.02
Common Stock	Non-Qualified Stock Option	Disposition	2024-03-14	69,521	$81.05	69,521	$81.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
33,881		2032-01-31	No	4	M	Direct
12,587		2029-02-07	No	4	M	Direct

Footnotes

Includes an aggregate of 162 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.
The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019. These options will expire ten years from the date of grant on February 07, 2029.